FDA Approval Alert: The Need-to-Know | Revumenib in Relapsed/Refractory KMT2A-Translocated Acute Leukemia
In November 2024, the FDA approved revumenib for the treatment of patients with relapsed/refractory acute leukemia harboring a KMT2A translocation in adult and pediatric patients 1 year and older.
FDA Approves Revumenib for Relapsed/Refractory KMT2A-Translocated Acute Leukemia
Article
By Gina Mauro
Nov 15, 2024 9:16 PM
The FDA has approved revumenib (Revuforj) for the treatment of patients with relapsed/refractory acute leukemia with a KMT2A translocation in adult and pediatric patients 1 year and older.
